{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:52:33Z","timestamp":1747194753214,"version":"3.40.5"},"reference-count":5,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In a double-blind randomised controlled trial by Asherson et al., involving prisoners with attention-deficit hyperactivity disorder (ADHD), the rates of response to osmotic-release oral system methylphenidate (OROS-methylphenidate) and placebo were very similar (~50%). I critically discuss this trial against other international literature, highlighting the key issues in the field in terms of clinical practice and research.<\/jats:p>","DOI":"10.1192\/bjp.2022.139","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T08:27:51Z","timestamp":1666254471000},"page":"4-6","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Methylphenidate for prison inmates with ADHD: yes or no?"],"prefix":"10.1192","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8075","authenticated-orcid":false,"given":"Samuele","family":"Cortese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"S0007125022001398_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw049"},{"key":"S0007125022001398_ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01134-w"},{"key":"S0007125022001398_ref3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.092940"},{"key":"S0007125022001398_ref2","article-title":"Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder (CIAO-II)","volume":"20","author":"Asherson","year":"2019","journal-title":"Br J Psychiatry"},{"key":"S0007125022001398_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.01.022"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125022001398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T08:53:11Z","timestamp":1671439991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125022001398\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0007125022001398"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2022.139","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"type":"print","value":"0007-1250"},{"type":"electronic","value":"1472-1465"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}